Clofazimine

Administration

• Type: Antibacterial
• Dosage Forms: CAP 50mg
• Routes of Administration: Oral
• Common Trade Names: Lamprene

Adult Dosing

Hansen disease, mutlibacillary

• 50mg PO qd x 12mo in combination with rifampin and dapsone
  • Give 300mg PO qmo x 12mo in addition to daily dose

Erythema nodosum leprosum

• 100mg PO bid x12wk, then 100mg PO qd 12-24wk
  • Start 100mg PO tid x12wek

Pediatric Dosing

Hansen disease, mutlibacillary

• 10-14 yo
  • 50mg PO qod AND 150mg PO qmo x12mo in combination with rifampin and dapsone
• 15+ yo
  • 50mg PO qd AND 300mg PO qmo x 12mo in combination with rifampin and dapsone

Special Populations

• Pregnancy Rating: Caution of use during pregnancy; obtain negative pregnancy test before starting
• Lactation risk: Caution advised

Renal Dosing

• Adult: Not defined
• Pediatric: Not defined

Hepatic Dosing

• Adult: Not defined
• Pediatric: Not defined

Contraindications

• Allergy to class/drug
• Caution:
  • Electrolyte abnormality
  • Congenital long QT syndrome
  • QT prolongation or family history
  • Torsades de pointes
  • Ventricular arrhythmias
  • Bradycardia
  • Recent MI
  • CHF

Adverse Reactions

Serious

• Abdominal sx, severe
• Hepatitis
• Jaundice
• Intestinal obstruction
• GI Bleeding
• Splenic infarction
• Thromboembolism
• QT Prolongation
• Torsades de pointes

Common

• Skin discoloration
• Nausea/Vomiting
• Diarrhea
• Abdominal/epigastric pain
• Ichthyosis/xeroderma
• Pruritus/rash
• Discolored urine/feces/sputum/sweat
• Ocular pigmentation
• Ocular irritation
• Hyperglycemia
• ESR elevated

Pharmacology

• Half-life: 70 days
• Metabolism: Unknown
• Excretion: Feces primarily

Mechanism of Action

• Bacteriostatic or bactericidal: Binds to mycobacterial DNA, inhibiting growth